Target Audience: Patients with CVI/varicose disease, athletes, post-operative patients, pregnant women, medical institutions, and pharmacies.
Lauma Medical Advantages: European quality (Latvia), 96% natural cotton, hypoallergenicity, various stretch levels (low, medium, high), bandages with fasteners, latex-free models.
| Brand | Origin | Size / Type | Price (BYN) | Per Meter |
|---|---|---|---|---|
| Lauma Medical | Latvia | 8 cm × 5 m / High | 21.05 - 23.60 | 4.21 - 4.72 |
| Lauma Medical | Latvia | 8 cm × 3 m / Medium | ~18 - 20 | 6.00 - 6.67 |
| Polza | Belarus | 8 cm × 5 m / Medium | 9.15 - 11.20 | 1.83 - 2.24 |
| Polza | Belarus | 10 cm × 5 m / Medium | 9.15 | 1.83 |
| Polza | Belarus | 12 cm × 5 m / Medium | 10.34 | 2.07 |
| Lenta | Belarus | 8 cm × 2 m / Comp. | 4.59 - 5.65 | 2.30 - 2.83 |
| Lenta | Belarus | 8 cm × 3.5 m / Comp. | 6.54 - 8.40 | 1.87 - 2.40 |
| Lenta | Belarus | 8 cm × 5 m / Comp. | 9.85 - 10.85 | 1.97 - 2.17 |
| Tonus Elast | Latvia | 10 cm × 5 m / Medium | ~15 - 18 | 3.00 - 3.60 |
| Tonus Elast | Latvia | 8 cm × 5 m / High | ~16 - 20 | 3.20 - 4.00 |
laumamedical.by and e-shop laumamedicalshop.by.| Channel | Priority | Strategic Action Plan |
|---|---|---|
| Medical & Orthopedic Chains | High | Contracts with TOP-5 networks, deployment of dedicated product stands. |
| Pharmacy Networks | High | Contracts with TOP-5 chains, dedicated shelf space optimization. |
| Digital Pharmacies | High | Listing and visibility on tabletka.by, apteka.103.by, i-apteka.by. |
| Medical Centers & Clinics | High | Direct procurement chains, top-down doctor recommendations. |
| Rehab Centers & Sanatoriums | High | Direct distribution contracts and specialist advocacy programs. |
| B2C E-commerce | High | Direct-to-consumer digital sales via laumamedicalshop.by website. |
| State Procurement (B2B) | High | Aggressive participation in state healthcare tenders and public auctions. |
| Marketplaces | Medium | Volume sales and logistical scaling via Ozon.by and Wildberries.by. |
Strategic sales expansion plans designed for rapid distributor activation and optimal market volume attainment:
| Year | Sales Target (€) | Volume (Units) | Distributors Network | Market Status |
|---|---|---|---|---|
| 2026 | €67,500 | 34,615 pcs | 3 (Launch from April) | 50% of total potential |
| 2027 | €210,000 | 107,692 pcs | 4 (3 at 100%, 1 at 50%) | Mixed scalability |
| 2028 | €270,000 | 138,462 pcs | 5 (4 at 100%, 1 at 50%) | Optimal performance |
| Year | Sales Target (€) | Volume (Units) | Distributors Network | Market Status |
|---|---|---|---|---|
| 2026 | €90,000 | 3,333 pcs | 1 partner node | 35% of total potential |
| 2027 | €330,000 | 12,222 pcs | 2 partners (65% & 35%) | Accelerated adoption |
| 2028 | €630,000 | 23,333 pcs | 3 partners (100%, 65%, 35%) | Full-scale saturation |
Strategic allocation to maximize medical professional outreach and digital asset building. Note: Budget expansion is critically recommended for social media, blogs, and electronic media via laumamedical.by.
| Marketing Channel / Activity | Budget (€) | Share (%) | Projected Target ROI |
|---|---|---|---|
| Medical Education (Doctors, Pharmacists, Phlebologists, Surgeons) | €2,025 | 30% | 1:4 (Long-term clinical advocacy) |
| Pharmacy Product Seeding & Demonstrations | €1,350 | 20% | 1:3 (Trial purchase conversions) |
| Digital Marketing & laumamedical.by Website Optimization | €1,350 | 20% | 1:2.5 (Direct acquisition traffic) |
| Healthcare Exhibitions & Event Participation | €1,013 | 15% | 1:2 (New B2B contract generation) |
| Printed Materials, Color Guides & Catalogues | €675 | 10% | 1:1.5 (General awareness support) |
| PR Campaigns & Targeted Mass Media Outreach | €337 | 5% | 1:2 (Brand trust building) |
| Indicator Metrics | 2026 Target | 2027 Target | 2028 Target |
|---|---|---|---|
| Total Combined Sales (€) | €157,500 | €540,000 | €900,000 |
| Total Marketing Investment (€) | €15,750 | €54,000 | €81,000 |
| Total Sampling Budget (Units) | 758 pcs | 1,199 pcs | 1,618 pcs |
Deployment of free product units to generate immediate clinical feedback and brand visibility:
To accelerate market penetration, a structured motivation matrix is deployed alongside commercial financial co-sharing:
| Plan Achievement Level | Bonus Reward | Contract Conditions |
|---|---|---|
| 100% – 110% | 2% of total purchase volume | Full execution of negotiated annual sales plan |
| 111% – 120% | 4% of total purchase volume | Plan over-fulfillment metrics achieved |
| > 120% | 6% of total purchase volume | Significant high-scale volume market over-fulfillment |
Co-Marketing Program: Lauma Medical funds up to 50% of the distributor’s local advertising costs, capped at a maximum of 20% of the total annual regional marketing budget per distributor.
| Identified Risk Factor | Probability | Impact | Mitigation & Prevention Guardrails |
|---|---|---|---|
| Distributor onboarding delays | Medium | High | Maintaining a standby list of 5 validated candidate partners; flexible contract terms. |
| Slow distributor potential build-up | Medium | Medium | Intensive 30-day "Fast Start" onboarding training, ongoing support by the representative. |
| Price wars with domestic brands | High | Medium | Aggressive focus on European quality parameters, 96% cotton texture, and therapeutic value. |
| Regulatory and registration shifts | Low | High | Continuous legal monitoring, proactive certificate management, and documentation reserves. |
| Regional economic instability | Medium | High | Flexible payment structures (70/30 or 50/50 options) and localized logistics warehousing. |
| Period | Strategic Focus | Action Items & Deliverables |
|---|---|---|
| April – May | Setup & Launch | Documentation package preparation, website creation, active negotiations with networks. |
| June – August | Activation Node 1 | Signing 3 bandage distributors and 1 hosiery partner; initiating initial product shipments. |
| June – August | Activation Node 2 | Staff training seminars, point-of-sale (POS) materials deployment, first sample seeding. |
| Sept – Nov | Market Growth | Sales performance data analysis, inventory corrections, onboarding preparation for D4 & D2. |
| December | Strategic Review | Signing contract updates for the 2027 cycle, annual evaluation, future budgeting loops. |
Monthly Baseline Operational Metrics: Average sales target of €2,250/mo per distributor (scaling to €4,200 in 2027 and €4,500 in 2028); 50 active pharmacies per network node (scaling to 80 and 100); dedicated **Shelf Share (Доля полок) of 15%** in Year 1 (targeting 25% and 30%); Inventory turnover of 6 times/year (scaling to 8 and 10).
Emergency Operational Buffers: If sales drop >20% below target lines, the system automatically activates a +5% marketing co-funding injection, immediate pharmacist retraining programs, and personal representative audits. In cases of critical distributor failure, transition to the backup partner list is initiated.
S.D. Filippov
Minsk, March 23, 2026